SCM
JUNO

Suffolk Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Suffolk Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-65,055
Closed -$1.95M – 169
2016
Q3 		$1.95M Sell
65,055
-459
-0.7% -$14.3K 0.27% 68
2016
Q2 		$2.52M Hold
65,514
– – 0.32% 90
2016
Q1 		$2.5M Sell
65,514
-3,334
-5% -$116K 0.33% 86
2015
Q4 		$3.03M Sell
68,848
-450
-0.6% -$22.3K 0.38% 65
2015
Q3 		$2.82M Buy
+69,298
New +$3.04M 0.37% 70

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Suffolk Capital Management's JUNO Position: Q4 2016 in Review

Suffolk Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 65,055 shares — an estimated $1.95M sold.

Suffolk Capital Management first reported a position in JUNO in Q3 2015 and held it in 5 quarters. The position peaked at $3.03M in Q4 2015. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

  • Suffolk Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Suffolk Capital Management sold 65,055 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $1.95M.
  • Suffolk Capital Management first reported a position in Juno Therapeutics, Inc. in Q3 2015 and held it in 5 quarters.
  • Suffolk Capital Management's Juno Therapeutics, Inc. position peaked at $3.03M in Q4 2015.
  • 159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on Suffolk Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.